Using brain stimulation to help patients prepare for weight loss surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to improve the long-term success of bariatric surgery for severe obesity by using non-invasive brain stimulation (tDCS) to enhance cognitive control over eating behaviors before the surgery. Participants will receive either active or sham tDCS stimulation at home, and their brain function will be monitored before and after the surgery to assess changes associated with weight loss. The study focuses on individuals with a high body mass index (BMI) and those who struggle with controlling their eating habits, which can impact surgical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects with severe or morbid obesity (determined by BMI \> 35 or 40 kg/m2, respectively) eligible for BS treatment in compliance with the current guidelines
* Subjects who meet reduced control over eating behavior (disinhibition) criteria in the Eating Habits Questionnaire

Exclusion Criteria:

* Subjects unable to provide informed consent and those unable to understand and cooperate with study-related procedures (based on the physician's discretion)
* Subjects with a personal history of ischemic heart disease, myocardial infarction, stroke, heart failure, and atrial fibrillation
* Subjects who have already undergone BS treatment in the past
* Pregnant subjects or subjects that plan on becoming pregnant during the study.
* Subjects deemed unsuitable for the study based on expert evaluation (e.g., by a physician or neuropsychologist) will be excluded.
* Subjects with dreadlocks (problematic for the EEG)

Where it's running

• Saint Anne's University Hospital
  Brno, Czechia, Czechia Recruiting
• Central European Institute of Technology Masaryk University
  Brno, Czechia, Czechia Recruiting

Study contacts

• Principal investigator: Irena Rektorová, Prof. — Cetral European Institute of Technology
• Study coordinator: Petra Holštajn Zemánková, Dr.
• Email: petra.zemankova@mail.muni.cz
• Phone: +420 776 722 029

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.